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Background: Second cancer is the leading cause of death in lymphoma survivors, with lung cancer 
representing the most common solid tumor. Limited information exists about the treatment and prognosis 
of second lung cancer following lymphoma. Herein, we evaluated the outcome and prognostic factors of 
Lung Cancer in Lymphoma Survivors (the LuCiLyS study) to improve the patient selection for lung cancer 
treatment. 
Methods: This is a retrospective multicentre study including consecutive patients treated for lymphoma 
disease that subsequently developed non-small cell lung cancer (NSCLC). Data regarding lymphoma 
including age, symptoms, histology, disease stage, treatment received and lymphoma status at the time 
of lung cancer diagnosis, and data on lung carcinoma as age, smoking history, latency from lymphoma, 
symptoms, histology, disease stage, treatment received, and survival were evaluated to identify the significant 
prognostic factors for overall survival.
Results: Our study population included 164 patients, 145 of which underwent lung cancer resection. The 
median overall survival was 63 (range, 58–85) months, and the 5-year survival rate 54%. At univariable analysis 
no-active lymphoma (HR: 2.19; P=0.0152); early lymphoma stage (HR: 1.95; P=0.01); adenocarcinoma 
histology (HR: 0.59; P=0.0421); early lung cancer stage (HR: 3.18; P<0.0001); incidental diagnosis of lung 
cancer (HR: 1.71; P<0.0001); and lung cancer resection (HR: 2.79; P<0.0001) were favorable prognostic 
factors. At multivariable analysis, no-active lymphoma (HR: 2.68; P=0.004); early lung cancer stage  
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Introduction
Developments in modern chemotherapy and radiotherapy 
have increased the survival rate of lymphoma patients. The 
cure rate for patients with early stage Hodgkin lymphoma 
(HL) is generally ≥90%, and the 5-year survival rate 
(5-YSR) for patients with non-HL ranges from 26% to 
73%, depending on the stage and the aggressiveness of the 
disease (1). However, lymphoma survivors develop second 
primary malignancies with a higher rate than people of the 
same age, and sex in the general population (2). Established 
risk factors for lung cancer include radiotherapy, and 
alkylating-agent chemotherapy as well as smoking (3,4). 
During prolonged follow-up after initial treatment of 
lymphoma, the mortality of lung cancer overcomes that 
of lymphoma, and it represents the main cause of death 
in lymphoma survivors (5). Nevertheless, only few studies 
(1,6-8) have evaluated the outcome of lymphoma survivors 
who developed lung cancer as second primary malignancy. 
Thus, it is still unclear whether standard treatment options 
for lung cancer are limited or not by lymphoma.
In this study, we evaluated the outcome and prognostic 
factors of Lung Cancer in Lymphoma Survivors (the 
LuCiLyS study) in order to improve the patient selection 
for lung cancer treatment. 
Methods
Study design
This is a retrospective multicenter study. Consecutive 
patients who developed non-small cell lung cancer 
(NSCLC) as second primary cancer after lymphoma 
diagnosis, were identified from data base or medical records 
of each participating institution. A minimum latency of 
2 months between lymphoma and diagnosis of NSCLC 
was required, which is the standard latency generally 
adopted to exclude synchronous primary cancers (6-8). We 
excluded from the analysis: (I) patients with a different 
histological diagnosis from NSCLC (i.e., neuroendocrine, 
carcinoid, small cell carcinoma, oat cell carcinoma, 
sarcoma, and mesothelioma histology) as the natural 
history, as treatment, and/or outcome of these histologic 
subtypes differ from those of NSCLC; (II) patients with 
simultaneous diagnosis of lung carcinoma and lymphoma; 
(III) patients diagnosed with an additional second 
malignancy before and after their diagnosis of NSCLC, as 
it was difficult to understand whether previous lymphoma 
or second malignancy affected lung cancer outcome; 
(IV) patients with incomplete follow-up. 
The end-points of the paper were to evaluate post-
operative morbidity and mortality of lung cancer resection 
and prognostic risk factors of overall survival. The study 
design was approved by Local Ethics Committees of 
University of Campania Luigi Vanvitelli (approvation 
code: 228/19), coordinating center of the study, and then 
approved by each participating center. All patients gave a 
written informed consent for the surgical treatment and 
were aware that all information could be used anonymously 
for scientific purpose only. 
Data abstraction
The following data were recorded for each patient: gender, 
smoking history, age at diagnosis of lymphoma and at 
(HR: 2.37; P<0.0001); incidental diagnosis of lung cancer (HR: 2.00; P<0.0001); and lung cancer resection 
(HR: 2.07; P<0.0001) remained favorable prognostic factors. Patients with non-active lymphoma (n=146) 
versus those with active lymphoma (n=18) at lung cancer diagnosis presented better median survival (64 
vs. 37 months; HR: 2.4; P=0.02), but median lung cancer specific survival showed no significant difference  
(27 vs. 19 months; HR: 0.3; P=0.17).
Conclusions: The presence and/or a history of lymphoma should not be a contraindication to resection of 
lung cancer. Inclusion of lymphoma survivors in a lung cancer-screening program may lead to early detection 
of lung cancer, and improve the survival. 
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diagnosis of NSCLC, stage, and histology of lymphoma; 
treatment given for lymphoma including radiotherapy, 
chemotherapy or combined radio-chemotherapy, histology 
and stage of NSCLC re-classified based on the latest, 8th 
edition of TNM staging system, treatments given for lung 
carcinoma including surgery, chemotherapy, radiotherapy 
or combined chemo-radiotherapy. For patients undergoing 
lung cancer resection, we also evaluated the type of 
resection and post-operative morbidity and mortality. 
Operative mortality was defined as any death within 30 days 
of operation or prior to discharge. 
Survival 
End points of the analysis included overall survival, and 
lung cancer specific survival. Overall survival was measured 
from the date of surgery until death. Patients without events 
were censored at the time of last follow up. Lung cancer 
specific survival was calculated from the date of surgery 
until death due to lung cancer. 
Statistical analysis
Data were reported as mean ± standard deviation (SD), or 
median and interquartile range for continuous variables or 
as number and percentages for categorical variables. The 
chi-square test and Fisher’s exact test were performed to 
evaluate significant differences of proportions or percentages 
between two groups. Particularly Fisher’s exact test was used 
where the chi-square test was not appropriate. Significant 
difference between two means was evaluated with Student’s 
t-test. Survival curves were calculated by the Kaplan-Meier 
method, and differences assessed by log-rank test. Univariate 
analysis was performed and the hazard ratio (HR) with 
confidence interval at 95% were evaluated to compare two 
conditions or states, in this way we identified the prognostic 
factors influencing the overall survival. The variables 
reaching statistically significant difference entered into a 
multivariate regression analysis with forward selection and 
backward elimination, using death as endpoint (dependent 
variable). A P<0.05 was considered statistically significant. We 
used MedCalc statistical software (Version 12.3, Broekstraat 
52; 9030 Mariakerke; Belgium) for all statistical analyses
Results
One hundred and seventy-nine patients with lung cancer 
diagnosis and a history of lymphoma were retrospectively 
identified; of these, 15 patients were excluded due to 
a different histological diagnosis from NSCLC (n=7), 
presence of additional second malignancy before diagnosis 
of NSCLC (n=3), or incomplete follow-up (n=5). Thus, our 
Table 1 Characteristics of lymphoma (n=164)
Variables Number [%]
Gender (male/female) 123 [75]/41 [25]
Smokers 130 [79]/34 [21]
Age at lymphoma diagnosis (years) 49±15
≤29 26 [16]
30–39 39 [24]
40–49 71 [43]
≥50 28 [17]
Lymphoma B symptoms
No 84 [51]
Yes 45 [27]
Unknown 35 [22]
Lymphoma stage
I 63 [38]
II 46 [28]
III 39 [24]
IV 16 [10]
Lymphoma classification
Hodgkin disease 21 [13]
Non-Hodgkin disease 143 [87]
Follicular cell lymphoma 69 [42]
Diffuse large B-cell lymphoma 44 [27]
T-cell lymphoma 2 [1]
Mantle cell lymphoma 10 [6]
MALT lymphoma 14 [9]
Burkitt lymphoma 4 [2]
Treatment of lymphoma
RT alone 74 [45]
CT alone 54 [33]
RT + CT 27 [16]
RT + CT + surgery 9 [5]
CT, chemotherapy; RT, radiotherapy; MALT, mucosa-associated 
lymphoid tissue.
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study population included 164 patients. 
Lymphoma data
Data are summarized in Table 1. The mean age at lymphoma 
diagnosis was 49±15 years. The majority of patients were 
male (n=123/164; 75%) and smokers (n=155/164; 95%), 
presented no lymphoma B symptoms (n=84/164; 51%), 
and had stage I (n=63/164; 38%) disease. The most 
common type of lymphoma was NHD (n=143/164; 87%), 
and follicular cell lymphoma was the most represented 
histological subtype (n=69/143; 48%). If considering 
lymphoma treatment,  74 (45%) patients received 
radiotherapy (RT), 54 (33%) chemotherapy (CT), 27 (16%) 
CT associated with RT, and 9 (5%) patients a combined 
treatment with RT, CT and surgery including splenectomy 
(n=6), gastrectomy (n=1), or intestinal resection (n=1). 
Lung cancer data
Data are summarized in Table 2. The mean age at lung cancer 
diagnosis was 57±9.7 years, and most patients were smokers 
(142/164; 87%). The mean latency between diagnosis 
of lymphoma and that of lung cancer was 8.8±2.1 years, 
with 79% of patients who developed lung cancer >5 years 
following lymphoma diagnosis (peak of incidence between 
5 and 10 years: 55%). In most cases (n=134; 82%) patients 
were asymptomatic, and the lung cancer detection was made 
incidentally on chest X-RAY or chest computed tomography 
scan performed during lymphoma follow-up, lung cancer 
screening program, and preoperative screening for other 
surgical procedures (i.e., inguinal hernia, cataract etc.). The 30 
(18%) remaining patients presented with signs and symptoms 
related to lung cancer. The most common histological 
types of lung cancer were adenocarcinoma (n=110/164; 
67%). One hundred and six (65%) patients presented stage 
I, 29 (18%) stage II, 18 (11%) stage III, and 11 (7%) stage 
IV disease. Lung cancer resection was performed in 145 
patients out of 164 (88%) including lobectomy (n=114; 
79%), sublobar resection (n=21; 14%), bilobectomy (n=7; 
5%); and pneumonectomy (n=3; 2%) followed by adjuvant 
chemotherapy and/or RT, if indicated. The remaining 19 
(12%) patients underwent CT and/or RT due to the advanced 
stage of the tumor or unfit clinical condition. 
Post-operative morbidity and mortality, long-term follow-up
Data are summarized in Table 3. Twenty-three out of 
145 patients (16%) patients presented post-operative 
complications including air-leaks (n=10), atelectasis needing 
bronchoscopic aspiration (n=8), atrial fibrillation (n=4), and 
infection of surgical site (n=1). One patient (0.6%) died 
25 days after pneumonectomy for acute respiratory distress 
syndrome (ARDS).
During the follow-up, 68 (41%) patients died due 
to recurrence or metastasis from lung cancer (n=31; 
20%) or lymphoma (n=12; 7.3%), Acute Myocardial 
Infarction (n=13; 8%), respiratory failure (n=7; 4%); and 
cerebrovascular accident (n=5; 3%). 
Lymphoma status
At the time of lung cancer diagnosis, 146 (89%) out of 
164 patients were in complete clinical remission, while the 
remaining 18 (11%) patients presented active lymphoma. 
As summarized in Table 2, the comparison of active 
lymphoma versus non active lymphoma group showed 
no significant difference regarding the different lung 
cancer variables: age at lung cancer diagnosis (55±9.7 vs. 
57±8.3 years; P=0.63), latency between lymphoma and 
lung cancer diagnosis (8.3±3.1 vs. 8.8±4.1 years; P=0.67); 
incidental diagnosis (83% vs. 72%; P=0.90); pre-operative 
morbidity (38% vs. 51%, P=0.31), histology and stage 
disease, lung cancer resection (83% vs. 89%; P=0.41); 
post-operative morbidity (11% vs. 14%; P=0.12) and 
post-operative mortality (0 vs. 0.6%; P=0.72). “Active 
lymphoma” had a higher rate of death due to lymphoma 
recurrence or metastasis  than that of “no active” 
lymphoma group (22% vs. 5.4%, P=0.01). 
Survival 
The median overall survival after the diagnosis of lung 
cancer was 63 (range, 58–85) months, and the 5-YSR was 
54% (Figure 1). 
Lymphoma characteristics
Median overall survival of patients with age ≤29; 30–39; 
40–49; ≥50 years was 63 (range, 16–73); 59 (range, 24–64); 
67 (range, 60–85); 42 (range, 28–72); 63 (range, 59–85) 
months, respectively. No significant difference was 
found among patient groups stratified according to age 
at lymphoma diagnosis (P=0.20; Figure 2A). Survival of 
HL patients compared to that of NHL patients showed 
no significant difference [67 (range, 24–85) vs. 61 (range, 
51–85) months; HR: 1.1 (0.59–2.42); P=0.65]; among NHL 
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Table 2 Characteristics of lung cancer (n=164)
Variables Total population (n=164) Active lymphoma (n=18) No active lymphoma (n=146) P value
Age at lung cancer 
diagnosis
57±9.7 55±9.7 57±8.3 0.63
≤59 years 68 [41] 7 [39] 61 [42] 0.77
60 to 69 years 65 [40] 9 [50] 56 [38] 0.37
≥70 years 31 [19] 2 [11] 29 [20] 0.76
Latency between 
lymphoma and lung 
cancer diagnosis
8.8±2.1 8.3±3.1 8.8±4.1 0.67
≤5 years 34 [21] 2 [11] 32 [22] 0.6
>5 to 10 years 90 [55] 10 [56] 80 [55] 0.99
>10 to 15 years 30 [18] 4 [22] 26 [18] 0.7
>15 years 10 [6] 2 [11] 8 [5] 0.43
Pre-operative morbidity 81 [49] 7 [39] 74 [51] 0.31
COPD 19 [12] 2 [11] 17 [11.6]
Cardiac disease 20 [12] 2 [11] 18 [12.3]
Vascular disease 10 [6] 1 [6] 9 [6]
Diabetes 15 [9] 1 [6] 14 [10]
Renal failure 3 [2] – 3 [2]
Others 14 [9] 1 [6] 13 [9]
Symptoms at time of lung 
cancer diagnosis
No symptoms 134 [82] 15 [83] 119 [82] 0.9
Symptoms* 30 [18] 3 [17] 27 [18] 0.79
Cough 9 [5] 3 [2] 6 [4]
Pneumothorax 1 [0.6] – 1 [0.6]
Hemoptysis 5 [3] – 5 [3]
Pleural effusion 3 [2] – 3 [2]
Chest pain 10 [6] 1 [6] 10 [7]
Dyspnea 13 [8] 1 [6] 13 [9]
Pneumonia 2 [1] – 2 [1]
Histology of lung cancer
Adenocarcinoma 110 [67] 11 [61] 99 [68] 0.52
Squamous cell 
carcinoma
42 [26] 5 [28] 37 [25] 0.87
Large cell carcinoma 12 [7] 2 [11] 10 [7] 0.59
Table 2 (continued)
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Table 2 (continued)
Variables Total population (n=164) Active lymphoma (n=18) No active lymphoma (n=146) P value
Stage disease (8th edition)
IA1 40 [24] 5 [28] 35 [24] 0.77
IA2 29 [18] 2 [11] 27 [18] 0.4
IA3 21 [13] 2 [11] 19 [13] 0.76
IB 16 [10] 1 [6] 15 [10] 0.47
IIA 6 [3] 2 [11] 4 [3] 0.07
IIB 23 [14] 3 [17] 20 [14] 0.79
IIIA 15 [9] 2 [11] 13 [9] 0.83
IIIB 3 [2] 0 3 [2] 0.54
IV 11 [7] 1 [6] 10 [7] 0.83
Treatment of lung cancer
Surgical resection 145 [88] 15 [83] 130 [89] 0.41
Lobectomy 114 [78] 12 [80] 102 [70] 0.68
Wedge resection 10 [7] 1 [1] 9 [6] 0.83
Segmentectomy 11 [8] 1 [1] 10 [7] 0.76
Bilobectomy 7 [5] 1 [1] 6 [4] 0.88
Pneumonectomy 3 [2] 0 3 [2] 0.54
No resection 19 [22] 3 [17] 16 [11] 0.54
*, some patients presented more than one symptom.
Table 3 Post-operative morbidity, post-operative mortality, cause of death
Variables
Total population 
(n=164)
Active lymphoma 
(n=18)
No active lymphoma 
(n=146)
P value
Post-operative morbidity 23 [14] 2 [11] 21 [14] 0.12
Air leaks 10 [6] 1 [6] 9 [6]
Atelectasis 8 [5] 1 [6] 7 [5]
Atrial fibrillation 4 [3] – 4 [3]
Infection of surgical site 1 [1] – 1 [1]
Post-operative mortality 1 [1] – 1 [0.7] 0.72
Cause of death 68 [41] 11 [61] 57 [39] 0.08
Recurrence or metastasis lung cancer 31 [19] 3 [17] 28 [19] 0.74
Recurrence or metastasis lymphoma 12 [7] 4 [22] 8 [5.5] 0.01
Other medical conditions 25 [15] 4 [22] 21 [14] 0.43
Myocardial ischemia 13 [8] 2 [11] 11 [8]
Respiratory failure 7 [4] 1 [6] 6 [4]
Cerebral Ictus 5 [3] 1 [6] 4 [3]
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patients the comparison of survival among patient groups 
stratified according to different histology also showed no 
significant difference (P=0.11, Figure 2B). The overall 
survival for patients with stage I; stage II; stage III; and stage 
IV lymphoma were 67 (range, 61–75); 72 (range, 59–85); 
45 (range, 19–48); 51 (range, 14–59) months, respectively; 
no significant difference was found among patient groups 
stratified according to lymphoma stage (P=0.08; Figure 2C). 
The overall survival for patients undergoing radiotherapy 
(RT); chemotherapy (CT); RT plus CT; RT + CT + surgery 
were: 60 (range, 41–85); 61 (range, 41–85); 72 (range, 
51–75); 61 (range, 11–76) months, respectively. No significant 
difference was found among patient groups stratified according 
to lymphoma treatment (P=0.56; Figure 2D).
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Figure 1 The median overall survival after diagnosis of lung cancer 
was 63 (range, 58–85) months.
Figure 2 No significant difference was found among patients groups stratified according to age at lymphoma diagnosis (P=0.20; Part A); 
Non-Hodgkin lymphoma histology (P=0.11, Part B); lymphoma stage (P=0.08; Part C); and lymphoma treatment (P=0.56; Part D).
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Lung cancer characteristics
The median overall survival for patients with age ≤59; 60–69; 
and ≥70 years was: 63 (range, 18–73); 67 (range, 59–85); and 
60 (range, 40–85) months, respectively; and no significant 
difference was found among patients stratified according 
to age at lung cancer diagnosis (P=0.17; Figure 3A). 
The median overall survival for patients with latency 
between lymphoma and lung cancer diagnosis ≤5; >5 to 10; 
>10 to 15; and >15 years was: 48 (range, 28–75); 67 (range, 
59–85); 61 (range, 12–63), 48 (range, 13–79) respectively; 
no significant difference was found among patients 
stratified according to different latency (P=0.07; Figure 3B). 
Patients whose lung tumors were detected incidentally 
had a significantly better survival than that of symptomatic 
patients [67 (range, 63–85) vs. 28 (range, 18–45) months; 
HR: 5.3 (2.76 to 10.3); P<0.0001]. The overall survival for 
patients with stage I; stage II; stage III; and stage IV disease 
was: 76 (range, 64–85); 48 (range, 20–75); 21 (range, 13–41); 
11 (range, 7–17) months, respectively. Significant difference 
was found by the comparison of patients stratified according 
to different stage disease (P<0.0001; Figure 3C). The overall 
survival for patients with adenocarcinoma, squamous cell 
carcinoma, and large cell carcinoma was: 61 (range, 50–81); 
51 (range, 25–61); 43 (range, 20–59) months, respectively; 
no significant difference was found comparing patients 
stratified according to different histology (P=0.11). Patients 
undergoing lung cancer resection had better survival 
compared to that of non-surgical patients [64 (range, 60–85) 
Figure 3 No significant difference was found among patients stratified according to age at lung cancer diagnosis (P=0.17; Part A); latency 
between lymphoma and lung cancer diagnosis (P=0.07; Part B); and different type of resections (P=0.23; Part D), while significant difference 
was found among patients stratified according to lung cancer stage (P<0.0001; Part C).
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vs. 14 (range, 11–18) months; HR: 1.7 (2.8–4.7); P<0.0001]. 
No significant difference was found among patients 
stratified according to the different type of resections 
(P=0.23; Figure 3D).
Lymphoma status
Patients with lymphoma in remission presented a 
significantly better overall survival than those with active 
lymphoma [64 (range, 59–85) vs. 37 (range, 13–75) months; 
HR: 2.4 (1.09–5.49); P=0.02; Figure 4A]. The comparison 
of lung cancer specific survival showed no significant 
difference between no active lymphoma and active 
lymphoma patients [27 (range, 18–85) vs. 19 (range, 13–37) 
months; HR: 0.3 (0.05–1.70); P=0.17; Figure 4B].
Univariable and multivariable analysis for overall survival 
Data are summarized in Table 4. At univariable analysis no-
active lymphoma (HR: 2.19; P=0.0152); early lymphoma 
stage (HR: 1.95; P=0.01); adenocarcinoma histology (HR: 
0.59; P=0.0421); early stage of lung cancer (HR: 3.18; 
P<0.0001); incidental diagnosis of lung cancer (HR: 1.71; 
P<0.0001); and lung cancer resection (HR: 2.79; P<0.0001) 
were favorable prognostic factors. At multivariable analysis, 
no-active lymphoma (HR: 2.68; P=0.0043); early stage of 
lung cancer (HR: 2.37; P<0.0001); incidental diagnosis of 
lung cancer (HR: 2.00; P<0.0001); and lung cancer resection 
(HR: 2.07; P<0.0001) were confirmed to be favorable 
prognostic factors. 
Discussion
The increased risk of lung cancer among lymphoma 
survivors has been well described in several papers and 
meta-analyses (2-6), but limited information exists about the 
prognosis and treatment outcome of lung cancer. Milano 
et al. (7,8) and Kim et al. (9) evaluated survival of lymphoma 
patients who developed NSCLC, and matched them with 
non-lymphoma patients with de novo NSCLC. Both authors 
(7-9) found that lymphoma patients faced worse survival 
than did non-lymphoma patients. These findings supported 
the hypothesis that previous lymphoma adversely affect 
the survival and outcome of lung cancer treatment, but it 
is still unclear which lymphoma survivors with lung cancer 
could benefit from lung cancer resection. To investigate this 
issue, we evaluated the outcome and prognostic factors of 
lung cancer in lymphoma survivors in order to improve the 
patient selection for lung cancer treatment 
First, we found that the safety of surgery was not 
impacted by lymphoma, as the latter disease did not 
significantly increase post-operative morbidity and mortality 
rate. Twenty-three (16%) patients presented post-operative 
complications including air-leaks (7%), atelectasis needing 
bronchoscopic aspiration (5%), atrial fibrillation (3%), 
and infection of surgical site (1%) while only one patient 
(0.6%) died of ARDS 25 days after pneumonectomy. These 
complications seemed to be correlated to the underlying 
patient’s diseases as chronic obstructive pulmonary disease 
(COPD), diabetes, cardiac disease, and extent of lung 
resection rather than to previous lymphoma. Furthermore, 
no patients presented pneumonia that was the most 
Figure 4 Patients with lymphoma in remission compared with 
those with active lymphoma presented significant better survival 
[64 (range, 59–85) vs. 37 (range, 13–75) months; HR: 2.4; P=0.02; 
Part A], but lung cancer specific survival showed no significant 
difference [27 (range, 18–85) vs. 19 (range, 13–37) months; HR: 
0.3; P=0.17; Part B].
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common complication reported by other authors (10,11) 
in lymphoma survivors undergoing lung cancer resection, 
most likely due to the lymphoma related immunodeficiency. 
In line with our data, Kim et al. (9) found no significant 
difference in postoperative morbidity and mortality 
between lymphoma patients and no-lymphoma patients 
after lung cancer resection. However, the authors (9) 
reported a mortality rate of 6% that was three times 
higher after standard lobectomy compared to matched no-
lymphoma lung cancer patients. Therefore, these patients 
need more aggressive postoperative monitoring , especially 
in case of comorbid condition and extended resection such 
as pneumonectomy. 
Second, we observed in our series a median overall 
survival of 63 months (mean, 54.8±2.5 months) that was 
better than what reported by other authors. Schoenfeld 
et al. (1) showed a median survival time of 10.3 months 
even because two thirds of the patients (67%) presented 
an advanced stage disease, (stage III or stage IV). Laurie 
et al. (12) reported a median survival of 5.1 months, and no 
patient lived longer than 10.5 months. Complete resection 
was achieved in 5 cases and only 2 of which (25%) presented 
stage I disease. The remaining 14 patients did not undergo 
a complete resection, and showed a median survival of 
3.0 months. De Giacomo et al. (11) reported a 5-YSR of 20% 
and only 40% of patients had an early stage lung cancer. 
Das et al. (13) found a median survival of 9 months. Most 
patients (85%) presented at advanced disease stage (III or 
stage IV), and 40% underwent surgery. Yet, some patients 
presented different histology from NSCLC (i.e., small-cell 
lung cancer and mesothelioma). Riquet et al. (14) reported 
a 5-YSR of 38.1% (median 34 months), and 5 of 36 (14%) 
patients had pN2 disease. Thus, the higher percentage 
of patients with stage I lung cancer, as well as the higher 
rate of patients undergoing surgery, and the exclusion of 
those with different histology from NSCLC could explain 
our different results. This is further confirmed by Kim 
et al. (9) who reported a median overall survival duration 
of 53 months. All patients underwent surgery, and 70% 
presented Stage I disease. 
Third, we found that early lung cancer stage, no-active 
lymphoma status at the time of lung cancer diagnosis, lung 
cancer resection, and incidental diagnosis of lung cancer 
were favorable predictors for overall survival. Incidental 
diagnosis of lung cancer allowed to make diagnosis of 
cancer at an early stage with the possibility of surgical 
treatment. Similarly, in Schoenfeld’s series (1) the subgroup 
of HL patients (n=12) with subsequent incidentally 
diagnosed lung malignancy presented a significant longer 
survival time (median 48 months after initial diagnosis) 
than that of patients who presented with symptomatic lung 
disease. Surgery was the only therapeutic chance for these 
patients, because definitive thoracic radiotherapy would be 
precluded in most patients by prior mantle-field radiation 
therapy. This observation was also confirmed by Laurie 
et al. (12) who found that only patients who underwent 
Table 4 Univariable and Multivariable analysis (dependent variable: overall survival)
Covariates
Univariable Multivariable
Coefficient HR 95% CI P value Coefficient HR 95% CI P value
Sex (male vs. female) 0.42 1.52 0.81–2.84 0.19 
No active lymphoma (yes vs. not) 0.79 2.19 1.16–4.14 0.0152 1.00 2.68 1.36–5.26 0.0043 
Age at Lymphoma diagnosis (≤39 vs. ≥40 years) −0.03 0.97 0.74–1.29 0.85
Type of lymphoma (HL vs. NHL) 0.56 0.34 0.63–1.69 0.76
Stage of lymphoma (stage I–II vs. stage III–IV) 1.59 1.95 1.68–2.03 0.01 0.67 0.98 0.97–2.96 0.78
Treatment of lymphoma (RT alone vs. others) −0.19 0.83 0.63–1.09 0.18  
Age at NSCLC diagnosis (≤59 vs. ≥60 years) 0.21 1.24 0.87–1.76 0.24
Incidental diagnosis of lung cancer (yes vs. not) 0.54 1.71 1.41–2.08 <0.0001 0.69 2.00 1.48–2.70 <0.0001 
Histology of NSCLC (adenocarcinoma vs. others) −0.52 0.59 0.36–0.98 0.0421 0.19 1.20 0.67–2.15 0.53
NSCLC stage (stage I–II vs. stage III–IV) 1.16 3.18 2.28–4.24 <0.0001 0.86 2.37 1.60–3.51 <0.0001 
Lung cancer resection (yes vs. not) −2.45 2.79 2.98–3.65 <0.0001 0.86 2.07 1.51–2.75 <0.0001 
HL, Hodgkin lymphoma; NHL, non-Hodgkin lymphoma; RT, radiotherapy; NSCLC, non-small cell lung cancer.
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complete resection of their lung carcinoma were long-
term survivors. Active lymphoma adversely affected overall 
survival, but no significant difference was found in lung 
cancer specific survival between active lymphoma and no 
active lymphoma patients. These results may be explained 
since patients with active lymphoma died of lymphoma 
recurrence or metastasis in a significantly higher rate than 
patients with no-active lymphoma (P=0.01), while the 
mortality rate due to lung cancer recurrence or metastasis 
was similar between the two sub-groups (P=0.74). Our 
data were also confirmed by Kim et al. (9) who found no 
significant difference regarding lung cancer specific survival 
between active lymphoma patients and no-active lymphoma 
patients, despite active lymphoma, also in our series, was 
shown to be an adverse significant prognostic factor at 
multivariable analysis. Thus, patients with active lymphoma 
could achieve reasonable survival after lung cancer 
resection, but they should be carefully selected for surgery 
(i.e., early stage lung cancer, treatable NHL, and adequate 
cardio-respiratory function). Differently from other authors 
(7-9), we found that previous radiotherapy for lymphoma, 
different histological types of lymphoma, and older age did 
not significantly affect the overall survival. Milano et al. (7,8) 
found that different histology sub-types and radiotherapy 
for lymphoma significantly influenced survival. However, 
the authors (7,8) evaluated only patients with HL, and in 
their series previous RT for lymphoma significantly limited 
the possibility of radiotherapy treatment for NSCLC. 
Conversely, in our series including patients with NH and 
NHL, RT for lymphoma did not have a significant impact 
on survival, as only one of the 10 patients scheduled for 
RT did not receive full dose radiation due to previous 
irradiation for lymphoma. Kim et al. (9) found that older age 
was an adverse prognostic factor in patients with lymphoma 
and lung cancer. In our series, 22 of 31 patients (71%) older 
than 70 years had an early stage tumor, probably because 
they were more likely to undergo diagnostic workups for 
related symptoms than younger patients. This was also 
observed in Milano’s studies (7,8). Fifteen of these patients 
(72%) underwent lung cancer resection, and in 11 (73%) 
cases a sublobar resection rather than a more extended 
resection was carried out. This strategy allowed to reduce 
the risk of post-operative morbidity, without significantly 
affecting the oncological results (15,16). 
Fourth, the increased survival found in our patients with 
incidentally diagnosed lung cancer supported the usefulness 
of lung cancer screening in lymphoma survivors. The 
National Lung Screening Trial (NLST) found that CT 
screening reduced lung cancer deaths of 20% in high risk 
population (17). Based on these data, the National 
Comprehensive Cancer Network (NCCN) categorized 
patients with prior lymphoma as a high-risk group only 
if they are more than 50 years old and have a smoking 
history (18). It was recommended that those patients should 
have annual low-dose helical CT scan for 2 years (category 1) 
and should be considered for an annual screening if 
they are clinically fit for definitive treatment. However, 
Ibrahim et al. (4) in a recent meta-analysis supported these 
recommendations should be reconsidered for several 
reasons. The NLST study (17) did not include patients with 
prior lymphoma, and only 0.1% of patients were younger 
than 55 years of age. Moreover, the median age at the 
diagnosis of second lung cancer in Ibrahim et al. (4) meta-
analysis was 45.0 years, and the rate of developing second 
lung cancer remained high after 15 years of follow-up. Our 
results seemed to confirm this hypothesis as the incidence of 
lung cancer reached its peak at 5–10 years following primary 
lymphoma treatment (55%), and remained elevated after 10 
years of follow-up (24%). Thus, we also support the need 
for continued follow-up of these patients, also considering 
that screening for breast cancers in young women treated 
for HL has been recommended to start ~8 to 10 years after 
HL treatment (19). Therefore, we believe that lymphoma 
survivors should receive a closer follow-up than the general 
population. Following treatment of lymphoma, survivors 
tend to switch to health-care providers and often lose contact 
with their oncologists. Thus, it is essential that all physicians 
should promote appropriate investigations to screen second 
carcinomas, especially primary lung carcinomas in smokers 
and former smokers, keeping in mind that latency time to the 
development of further malignancies could be long. Smoking 
cessation and abstinence are likely to have the greatest 
impact on reducing the mortality from lung carcinoma in 
this population. Ibrahim’s meta-analysis (1) showed that 
approximately 80% of patients with second lung cancer had 
a history of smoking, and these data are in line with ours and 
many reported series. Travis et al. (20) showed that in 24% of 
lymphoma survivors, incidence of second lung cancer could 
be attributable to smoking alone, while other studies (21,22) 
found that the risk of developing second lung cancer was 
positively associated with increasing number of pack-years 
smoked. 
Study limitations
Our study presents several limitations that do not allow 
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to draw definitive conclusions. Due to the retrospective 
and the multicenter nature of the study, there was not 
a standardized treatment for lymphoma (i.e., different 
protocol and regimen of chemotherapy and radiotherapy) 
and for NSCLC (i.e., different type of resection), but the 
treatment depended on the era of diagnosis, and the choice 
of physicians in the treating center. In some cases, there was 
a lack of detailed information about the site of radiotherapy 
and/or tobacco history (i.e., number of pack-year), while 
other variables as weight loss and performance status were 
not considered. 
Conclusions
The history of lymphoma or an active lymphoma should not 
be considered a contraindication to surgical treatment of 
lung cancer in selected patients who present with early stage 
lung cancer and are clinically fit for surgery. The increased 
survival observed in patients with an incidentally diagnosed 
lung cancer supports the usefulness of lung cancer screening 
in lymphoma survivors to detect lung cancer at an early 
stage. Due to the limitations of a retrospective analysis, 
our results should be furtherly validated by a prospective 
randomized study. 
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